ArticleDiscover oncology2026
S100A13 transcriptionally activated by SP1 facilitates osteosarcoma metastasis.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multi-Modal Analysis of Programmed Cell Death Identifies Biomarkers and Informs Prognosis in Osteosarcoma.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundOsteosarcoma is a highly aggressive primary bone malignancy in which distant metastasis critically determines patient prognosis. However, the molecular drivers of metastasis remain incompletely understood, making the elucidation of these drivers a research priority.
methodsWe integrated single-cell and bulk RNA sequencing data to identify cell populations associated with metastasis and to screen for candidate therapeutic targets. Bioinformatics tools predicted upstream transcriptional regulators. Functional roles and transcriptional regulation were assessed via wound-healing, Transwell, and luciferase reporter assays.
resultsSingle-cell analysis of osteosarcoma heterogeneity identified the osteoblastic subcluster C2_OB as a major contributor to metastasis. cNMF analysis defined a metastasis-associated expression program (module 2) highly active in C2_OB, within which S100A13 emerged as a novel signature gene. S100A13 was overexpressed in osteosarcoma and correlated with metastasis and poor prognosis. Functional assays demonstrated that S100A13 promoted cell migration and invasion. Mechanistically, the transcription factor SP1 directly binds to the S100A13 promoter, activates its transcription, and thereby enhances the metastatic capacity of osteosarcoma cells.
conclusionThis study identifies S100A13 as a biomarker for osteosarcoma metastasis and poor prognosis, and delineates an SP1/S100A13 axis that drives metastatic progression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.